FLXN Profile
Flexion
Therapeutics, Inc. (FLXN) is a biopharmaceutical company that develops
and commercializes innovative therapies for the treatment of
musculoskeletal conditions. The company's products and services
include Zilretta, a non-opioid treatment for osteoarthritis knee pain,
and FX301, a sustained-release local anesthetic for postoperative
pain. Flexion Therapeutics is headquartered in Burlington,
Massachusetts.
Flexion Therapeutics had a market capitalization
of approximately $669 million. The company's total revenue for the
fiscal year 2020 was $67.3 million, representing an increase from
$51.3 million in the previous year. Net loss for the same period was
$127.1 million, an increase from a net loss of $104.8 million in the
previous year.
Flexion Therapeutics' products have the
potential to address significant unmet medical needs in the treatment
of musculoskeletal conditions. The company has a strong pipeline of
product candidates, and has formed strategic partnerships with a range
of organizations to expand the reach of its products and services.
The biopharmaceutical industry is subject to various risks,
including regulatory risks and competition from other companies.
However, Flexion Therapeutics' experienced management team, strategic
partnerships, and strong pipeline of product candidates should
position it well for continued success in the future.
Flexion
Therapeutics' stock is listed on the NASDAQ stock exchange under the
ticker symbol FLXN. Investors should carefully consider their
investment objectives, risk tolerance, and other factors before
investing in Flexion Therapeutics or any other biopharmaceutical
|
